PlainRecalls
FDA Drug Moderate Class II Terminated

PAPAVERINE HYDROCHLORIDE Injection, USP, 60 mg/2mL (30 mg/mL), packaged as a) 25 x 2mL Single Use Vials per box (NDC 72516-024-25) and b) 10 x 2mL Single Use Vials per box (NDC 72516-024-10); Manufactured for Oryza Pharmaceuticals, Inc.

Reported: April 13, 2022 Initiated: March 14, 2022 #D-0742-2022

Product Description

PAPAVERINE HYDROCHLORIDE Injection, USP, 60 mg/2mL (30 mg/mL), packaged as a) 25 x 2mL Single Use Vials per box (NDC 72516-024-25) and b) 10 x 2mL Single Use Vials per box (NDC 72516-024-10); Manufactured for Oryza Pharmaceuticals, Inc.

Reason for Recall

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

Details

Units Affected
a) 2,098 boxes; b) 700 boxes
Distribution
Nationwide in the U.S.A
Location
San Diego, CA

Frequently Asked Questions

What product was recalled?
PAPAVERINE HYDROCHLORIDE Injection, USP, 60 mg/2mL (30 mg/mL), packaged as a) 25 x 2mL Single Use Vials per box (NDC 72516-024-25) and b) 10 x 2mL Single Use Vials per box (NDC 72516-024-10); Manufactured for Oryza Pharmaceuticals, Inc.. Recalled by Vitae Enim Vitae Scientific, Inc.. Units affected: a) 2,098 boxes; b) 700 boxes.
Why was this product recalled?
Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 13, 2022. Severity: Moderate. Recall number: D-0742-2022.